CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?)

Welcome and Background Cancer or Not Cancer "Presentation" - Scott Eggener

Rationale for Nomenclature Change Gleason Grade 1 Cancer "Presentation" - Matthew Cooperberg

Reservations About a Nomenclature Change for Gleason Grade 1 Prostate Cancer "Presentation" - Adam Kibel

What is in a Name? Inadvertent Harm from the Designation and Label of 'Cancer' "Presentation" - Laura Esserman

Grade Group 1 Prostate Cancer: A Pathologist's Case for Cancer Classification 'Con' "Presentation" - Gladell Paner

Grade Group 1 Prostate Cancer: A Pathologist's Case for Cancer Classification 'Pro' "Presentation" - Theodorus van der Kwast

Prostate Cancer Classification Dilemma: Lessons from Breast and Colorectal Tumors "Presentation" - Jeffry Simko

Prostate Cancer Biopsy Sampling: Challenges in Grade Group 1 Classification "Discussion" - Lawrence True

Rethinking Cancer Treatment: Lessons from Breast to Prostate Cancer "Presentation" - Alastair Lamb

Where to Draw the Line? The Spatial Molecular Continuum from 'Normal' to GG1 to GG2 Prostate Cancer "Presentation" - Alastair Lamb

Active Surveillance in Prostate Cancer: Rethinking Gleason Grade Group 1 "Presentation" - Daniel Lin

Active Surveillance Challenges in Prostate Cancer Management "Presentation" - Laurence Klotz

MRI Impact on Grade Group 1 Prostate Cancer Detection in Australia "Presentation" - Declan Murphy

Active Surveillance vs. Watchful Waiting in Prostate Cancer Management "Presentation" - Caroline Moore

Prostate Cancer Risk Assessment: Beyond Gleason Pattern Ratios "Presentation" - Andrew Vickers

Modeling Prostate Cancer: Rethinking Grade Group 1 Classification "Presentation" - Ruth Etzioni

The Debate on Prostate Cancer Grading: Addressing Underdiagnosis and Overdiagnosis Concerns "Presentation" - Andrew Vickers

Rethinking Prostate Cancer Classification: The Cribriform Pattern Debate "Discussion"

Alternative Payment Models in Prostate Cancer: Nomenclature Impact "Presentation" - CJ Stimpson

Active Surveillance in Europe: Challenges and Heterogeneity "Presentation" - Derya Tilki

Prostate Cancer in Africa: Pathology Outcomes and Risk Profiles "Presentation" - Mohamed Jalloh

Prostate Cancer Diagnosis: MRI vs. Systematic Biopsy "Discussion"

Racial Disparities in Prostate Cancer Active Surveillance Outcomes "Presentation" - Quoc-Dien Trinh

Prostate Cancer Risk Assessment: Addressing Racial Equity Concerns "Discussion"

Renaming Gleason 6 Prostate Cancer: Patient Perspectives and Impacts "Presentation" - Howard Wolinsky

Patient Perspectives on Prostate Cancer: Quality of Life and Treatment Decisions "Presentation" - Leszek Izdebski

CDC's Role in Advancing Prostate Cancer Active Surveillance Research "Presentation" - Ingrid Hall

Prostate Cancer Nomenclature: Impact on Screening Guidelines "Presentation" - Timothy Wilt

Rethinking Grade Group 1 Prostate Cancer: UK's Paradigm Shift "Presentation" - Hashim Ahmed

Rethinking Prostate Cancer Diagnosis: UK vs US Approaches "Discussion"

Prostate Cancer Markers: Challenges in Differentiating Low-Risk Cases "Discussion"

Genomics in Prostate Cancer: Limitations in Active Surveillance "Presentation" - Felix Feng

Redefining Prostate Cancer: The Debate on Grade Group 1 Classification "Discussion"

Reclassifying Prostate Cancer: Clinical Implications of Grade Group 1 Nomenclature Change "Discussion"

Prostate Cancer Nomenclature Change: Impact on Advocacy and Patient Care "Discussion"

Prostate Cancer Nomenclature Change: Societal and Clinical Implications "Discussion"

Prostate Cancer Management: Rethinking Active Surveillance and Nomenclature "Discussion"

Exploring Financial Toxicity and Cultural Differences in Prostate Cancer Active Surveillance "Discussion"